That's a different trial.The announcement refers to Selfridge's...

That's a different trial.

The announcement refers to Selfridge's one:
https://clinicaltrials.gov/study/NCT05400122

However, it also mentions the following inclusion criteria:

"Subjects must have histologically confirmed locally advanced or metastatic colorectal adenocarcinoma or relapsed or refractory hematologic malignancy and have failed at least one standard line of chemotherapy. Participants will be eligible if they have either refused standard treatment regimens or if there is no standard approach to curative salvage therapy per National Comprehensive Cancer Network (NCCN) guidelines in the setting of relapsed/refractory disease."

Whilst I agree with @reon1 's statement that other even asx listed companies have also achieved CR's, it is important to note that these CORE-NK cells are essentially a building block of our future therapies and so far, the P1 trial in 3 patients with blood cancer (without addition of vactosertib) achieved
one CR after by the 100 day mark (disease stability by day 28)
the other two maintained disease stability.

So far we know that the addition of vactosertib 1 out of 3 patients achieved a CR by day 28 (faster than the phase 1A trial).

That's a great therapy by itself, not to mention an excellent starting material for future therapies.

Can someone remind me again what our current MC is in comparison to other asx listed companies that achieved CR's in patients with these types of cancer?